LITHIUM CARBONATE capsule

Krajina: Spojené štáty

Jazyk: angličtina

Zdroj: NLM (National Library of Medicine)

Aktívna zložka:

LITHIUM CARBONATE (UNII: 2BMD2GNA4V) (LITHIUM CATION - UNII:8H8Z5UER66)

Dostupné z:

State of Florida DOH Central Pharmacy

Spôsob podávania:

ORAL

Typ predpisu:

PRESCRIPTION DRUG

Terapeutické indikácie:

Lithium is indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. Lithium is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks. Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or dehydration, or sodium depletion, and to patients receiving diuretics, since the risk of lithium toxicity is very high in such patients. If the psychiatri

Prehľad produktov:

Lithium Carbonate Capsules USP 150 mg: Size ‘4’ two piece opaque white hard gelatin capsules imprinted with ‘150’ on body & ‘G220’ on cap. 300 mg: Size ‘2’ two piece flesh hard gelatin capsules imprinted with ‘300’ on body and ‘G221’ on cap. 600 mg: Size ‘0’ elongated two piece hard gelatin capsules flesh colored cap and opaque white colored body imprinted with ‘600’ on body and ‘G222’ on cap. They are supplied by State of Florida DOH Central Pharmacy as follows:

Stav Autorizácia:

Abbreviated New Drug Application

Súhrn charakteristických

LITHIUM CARBONATE - LITHIUM CARBONATE CAPSULE
STATE OF FLORIDA DOH CENTRAL PHARMACY
----------
LITHIUM CARBONATE CAPSULES USP
150 MG, 300 MG AND 600 MG
WARNING
LITHIUM TOXICITY IS CLOSELY RELATED TO SERUM LITHIUM LEVELS, AND CAN
OCCUR AT DOSES CLOSE TO
THERAPEUTIC LEVELS. FACILITIES FOR PROMPT AND ACCURATE SERUM LITHIUM
DETERMINATIONS SHOULD
BE AVAILABLE BEFORE INITIATING THERAPY (SEE DOSAGE AND
ADMINISTRATION).
DESCRIPTION
Each capsule for oral administration contains:
Lithium Carbonate USP . . . . . . . . 150 mg, 300 mg or 600 mg
_Inactive Ingredients:_
The capsules contain colloidal silicon dioxide, gelatin, sodium lauryl
sulfate, talc, titanium dioxide,
FD&C Blue No. 1, FD&C Red No. 40, D&C Yellow No. 10 and the imprinting
ink contains shellac,
isopropyl alcohol, dehydrated alcohol, butyl alcohol, propylene
glycol, strong ammonia solution,
potassium hydroxide and black iron oxide.
Lithium is an element of the alkali-metal group with atomic number 3,
atomic weight 6.94, and an
emission line at 671 nm on the flame photometer.
The empirical formula for Lithium Citrate is C H Li
O ; molecular weight 209.92. Lithium acts as an
antimanic.
Lithium carbonate USP is a white, light, alkaline powder with
molecular formula Li
CO and molecular
weight 73.89.
CLINICAL PHARMACOLOGY
Preclinical studies have shown that lithium alters sodium transport in
nerve and muscle cells and effects
a shift toward intraneuronal metabolism of catecholamines, but the
specific biochemical mechanism of
lithium action in mania is unknown.
INDICATIONS AND USAGE
Lithium is indicated in the treatment of manic episodes of Bipolar
Disorder. Bipolar Disorder, Manic
(DSM-III) is equivalent to Manic Depressive illness, Manic, in the
older DSM-II terminology.
Lithium is also indicated as a maintenance treatment for individuals
with a diagnosis of Bipolar
Disorder. Maintenance therapy reduces the frequency of manic episodes
and diminishes the intensity of
those episodes which may occur.
Typical symptoms of mania include pressure of speech, motor
hyperac